- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05411744
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
March 6, 2024 updated by: Pinki Bhatt, Rutgers, The State University of New Jersey
This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Latent tuberculosis infection (LTBI) or inactive tuberculosis, is a common disease found in patients with end-stage renal disease (ESRD) who are being considered for renal transplant (RT).
Approximately 5-15% of patients with LTBI will convert to an active form of TB, especially in patients with a weak immune system.
Given the morbidity and mortality associated with active TB disease along with the public health threat, LTBI is routinely treated in pre-transplant candidates.
While treatment with isoniazid (INH) for 9 months is the mainstay of therapy, its use poses some clinical challenges due to the prolonged duration of treatment, risk of adverse drug effects, and suboptimal compliance and treatment completion.
In addition to these challenges, the consequences of delays in transplant due to the time it takes to complete current treatment options are notable.
Most recently, there is a large international, randomized, prospective, phase 3 clinical trial by Swindell et al., that found that 1 month of INH and Rifapentine (1m-INH-RPT) compared to the standard 9-month regimen of INH in HIV patients with LTBI had similar TB incidence in both treatment arms but higher compliance rate and fewer adverse events for patients taking 1m-INH-RPT.
Given these findings, if a similar study can be conducted in renal transplant candidate population, it can alleviate the aforementioned challenges being faced in RT candidates.
Thus, this is a single-arm, open-label, prospective clinical trial investigating the safety, compliance, pharmacokinetics of 1m-INH-RPT in RT candidates.
Study Type
Interventional
Enrollment (Estimated)
25
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pinki J Bhatt, MD
- Phone Number: 7329392610
- Email: pb518@rwjms.rutgers.edu
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Recruiting
- Pinki J Bhatt
-
Contact:
- Pinki J Bhatt
-
Principal Investigator:
- Pinki J Bhatt, MD
-
Principal Investigator:
- Navaneeth Narayanan, PharmD, MPH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Men and Women Age > 18
- Weight > 30 kg
- End-stage renal disease
- Living-related or deceased kidney transplant candidate (not on the waitlist) deemed by their transplant nephrologist
- Negative serum OR urine pregnancy test
- Evidence of latent tuberculosis or high risk for tuberculosis: (1) Confirmed positive tuberculin skin test (TST) ≥ 5 mm or positive quantiferon gold test/T-spot and a chest radiograph or chest CT scan without evidence of active pulmonary TB OR (2) Patients with negative TST or quantiferon gold/T-spot test but high risk for tuberculosis are eligible if they have (i) radiographic evidence of previous TB (stable fibronodular changes, including scarring [peribronchial fibrosis, bronchiectasis, and architectural distortion] and nodular opacities in the apical and upper lung zones) and no history of adequate treatment, or (ii) have had close and prolonged contact with a case of active TB.
Exclusion Criteria:
- Age <18 years
- Absolute neutrophil count of <750 cells/mm3
- Hemoglobin < 7.4 g/dL
- Platelets < 50 x 10E3/uL
- AST (SGOT) and ALT (SGPT) > 3 times the upper limit of normal (ULN)
- Total bilirubin > 2.5 times the ULN
- Presence of active TB
- Prior history of treatment for active TB or LTBI
- Known exposure to multidrug-resistant TB
- Known history of or active porphyria
- History of liver cirrhosis
- Evidence of active acute hepatitis
- Peripheral neuropathy > grade 2
- Active drug or alcohol dependence in opinion of investigator that will interfere with adherence
- On non-modifiable medications with significant drug interactions with Rifapentine or INH
- On medications known to cause hepatoxicity and/or neutropenia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1 month Rifapentine, Isoniazid and Vitamin B6
Participants will receive 28 days of self-administered daily doses of RPT, INH, and pyridoxine (vitamin B6). There are no multiple arms or multiple interventions. All participants will receive all 3 drugs. There are no comparators. |
Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of adverse events with 1-m INH/RPT/Vit B6
Time Frame: 28 days
|
Treatment discontinuation due to adverse reaction of study drug determined by investigator
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of treatment compliance
Time Frame: 28 days
|
Percentage of daily dosage taken within the 28 day course
|
28 days
|
Rate of treatment completion
Time Frame: 28 days
|
Completion of 28 day course within a 5 week period
|
28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of reactivation of active tuberculosis
Time Frame: 2 years
|
Rate of culture-confirmed tuberculosis disease after completing study regimen
|
2 years
|
Trough drug concentration
Time Frame: 28 days
|
Isoniazid and Rifapentine serum drug concentration
|
28 days
|
3-hour post-dose drug concentration
Time Frame: 28 days
|
Isoniazid and Rifapentine serum drug concentration
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Pinki Bhatt, MD, Rutgers
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7. doi: 10.1164/rccm.200905-0795OC. Epub 2009 Sep 3.
- Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808.
- Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998 Nov;27(5):1266-77. doi: 10.1086/514993.
- Subramanian A, Dorman S; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant. 2009 Dec;9 Suppl 4:S57-62. doi: 10.1111/j.1600-6143.2009.02894.x. No abstract available.
- Adamu B, Abdu A, Abba AA, Borodo MM, Tleyjeh IM. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. Cochrane Database Syst Rev. 2014 Mar 4;2014(3):CD008597. doi: 10.1002/14651858.CD008597.pub2.
- Agarwal SK, Gupta S, Dash SC, Bhowmik D, Tiwari SC. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol. 2004;36(3):425-31. doi: 10.1007/s11255-004-6251-6.
- Rafiei N, Williams J, Mulley WR, Trauer JM, Jenkin GA, Rogers BA. Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort. Nephrology (Carlton). 2019 May;24(5):569-574. doi: 10.1111/nep.13386.
- van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009 Mar;53(3):849-62. doi: 10.1128/AAC.00749-08. Epub 2008 Dec 15. No abstract available.
- Holland DP, Sanders GD, Hamilton CD, Stout JE. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One. 2011;6(7):e22276. doi: 10.1371/journal.pone.0022276. Epub 2011 Jul 18.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2022
Primary Completion (Estimated)
June 30, 2025
Study Completion (Estimated)
June 30, 2029
Study Registration Dates
First Submitted
June 6, 2022
First Submitted That Met QC Criteria
June 6, 2022
First Posted (Actual)
June 9, 2022
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Urologic Diseases
- Disease Attributes
- Renal Insufficiency
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Renal Insufficiency, Chronic
- Mycobacterium Infections
- Latent Infection
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Kidney Failure, Chronic
- Tuberculosis
- Latent Tuberculosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Leprostatic Agents
- Vitamins
- Vitamin B Complex
- Antitubercular Agents
- Antibiotics, Antitubercular
- Fatty Acid Synthesis Inhibitors
- Rifapentine
- Vitamin B 6
- Pyridoxal
- Pyridoxine
- Isoniazid
Other Study ID Numbers
- Pro2018001735
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on 1 month Rifapentine, Isoniazid and Vitamin B6
-
National Institute of Allergy and Infectious Diseases...CompletedTuberculosisHaiti, Kenya, Thailand, Malawi, Zimbabwe
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | TuberculosisBrazil, United States, Kenya, Peru, South Africa, Thailand, Botswana, Haiti, Malawi, Zimbabwe
-
The HIV Netherlands Australia Thailand Research...King Chulalongkorn Memorial Hospital; Srinagarind Hospital, Khon Kaen University and other collaboratorsActive, not recruitingHIV-infected Participants With Latent TB Infection in High TB Burden CountryThailand
-
St. Louis UniversityWithdrawn
-
National Institute of Allergy and Infectious Diseases...ViiV HealthcareSuspendedHIV Infection | LTBIUnited States, Haiti, Botswana, Brazil, Thailand, Zimbabwe, Malawi, Peru, South Africa
-
National Taiwan University HospitalUnknownLatent Tuberculosis InfectionTaiwan
-
Huashan HospitalShanghai First Maternity and Infant HospitalUnknownInfertility, Female | Recurrent Implantation Failure | Genital Tuberculoses, Female | Genital Tuberculosis, LatentChina
-
Milton S. Hershey Medical CenterAmerican Heart AssociationNot yet recruitingPeripheral Artery Disease | Ischemia Reperfusion Injury
-
Dr. Nyanda Elias NtinginyaKing's College London; Makerere University; Stichting Katholieke Universiteit-... and other collaboratorsRecruitingDiabetes Mellitus | TuberculosisUganda, Tanzania
-
National Taiwan University HospitalCompleted